<DOC>
	<DOCNO>NCT00075231</DOCNO>
	<brief_summary>The purpose study determine whether simplify lopinavir-ritonavir base therapy continue keep viral load low level initial treatment combination Kaletra® ( lopinavir/ritonavir ) plus Combivir® ( lamivudine/zidovudine ) .</brief_summary>
	<brief_title>A Simplified Kaletra® ( Lopinavir/Ritonavir ) -Based Therapy Versus Sustiva® ( Efavirenz ) -Based Standard Care Previously Non-Treated HIV-Infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Inclusion Criteria Subject least 18 year age . Subject confirm HIV positive investigator 's opinion require antiretroviral ( ARV ) therapy . Subject naïve HIV ARV therapy receive &lt; 7 day total HIV ARV therapy &gt; 30 day prior study drug administration . Subject 's HIV RNA &gt; = 1000 copies/mL screen . If sexually active , subject agrees use safe sex practice reduce risk HIV transmission ( e.g. , male female condom , vaginal dam , etc. ) . If female , result urine pregnancy test perform screening Day 1/Baseline negative . If female , subject either childbearing potential , defined postmenopausal least 1 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) , childbearing potential practice one follow method birth control : A . Condoms , sponge , foam , jelly , diaphragm intrauterine device . B . A vasectomized partner . C. Total abstinence sexual intercourse . Subject breastfeeding . Subject 's vital sign , physical examination , laboratory result exhibit evidence acute illness . Subject Karnofsky score great equal 70 . Subject agrees take drug study , include overthecounter medicine , vitamin , mineral supplement , herbal preparation , alcohol , recreational drug without knowledge permission investigator . Subject treat active AIDSdefining opportunistic infection within 30 day initiate study drug . Subject voluntarily sign date informed consent form , approve Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) , nature study explain subject opportunity ask question . The informed consent must sign studyspecific procedure perform . Exclusion Criteria A subject exclude study he/she meet follow criterion : Subject history allergic reaction significant sensitivity lopinavir , ritonavir , lamivudine , zidovudine , efavirenz , inert material contain study drug formulation . Subject significant history cardiac , renal , neurologic , psychiatric , oncologic , endocrinologic , metabolic , hepatic disease would , opinion investigator , adversely affect his/her participation study . Subject currently take drug ( medicinal herbal ) contraindicate and/or coadministered three study drug define current locally approve prescribing information . Subject history drug and/or alcohol abuse psychiatric illness investigator 's opinion could preclude compliance protocol . Subject receive immunomodulatory agent , colony stimulate factor , bone marrow stimulant ( e.g. , erythropoietin [ Procrit® , Epogen® ] filgrastim [ Neupogen® ] ) , ganciclovir , interferonalpha , bone marrow suppressive cytotoxic agent . The TRUGENE HIV1 resistance report indicate resistance possible resistance study reverse transcriptase inhibitor ( ) [ RTI ( ) ] ( efavirenz , lamivudine zidovudine ) OR presence mutation protease gene lead amino acid substitution follow locus : 8 , 30 , 32 , 46 , 47 , 48 , 50 , 54 , 82 , 84 , 90 OR four mutation follow locus : 10 , 20 , 24 , 36 , 53 , 63 , 71 . Screening laboratory analysis show follow abnormal laboratory result : Presence Hepatitis B surface antigen ( HBsAg ) ; Hemoglobin &lt; = 9.5 g/dL ; Absolute neutrophil count &lt; = 1000 cells/mL ; Platelet count &lt; = 50,000 per mL ; ALT ( SGPT ) AST ( SGOT ) &gt; = 3.0 x Upper Limit Normal ( ULN ) ; Fasting Triglycerides &gt; 750 mg/dL ; Fasting Cholesterol &gt; 300 mg/dL ; Creatinine &gt; = 1.5 x Upper Limit Normal ( ULN ) ; Fasting serum glucose &gt; 126 mg/dL Subject take prescribed lipid lower medication HMGCoA Reductase Inhibitors ( statin ) fibrate medication . Subject history diabetes mellitus . Subject receive investigational drug vaccine within 30 day prior study drug administration . For reason , subject consider investigator unsuitable candidate participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Treatment Naive</keyword>
</DOC>